BiotechTube

Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity

Trial Timeline

Jun 27, 2024 → Feb 12, 2025

NCT ID
NCT06515418

About Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo

Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo is a phase 2 stage product being developed by Eli Lilly for Obesity. The current trial status is terminated. This product is registered under clinical trial identifier NCT06515418. Target conditions include Obesity.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)
✅exenatide + PlaceboEli LillyApproved
✅TirzepatideEli LillyApproved
✅Micafungin + MicafunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Zonegran + PlaceboEisaiApproved
✅lorcaserin hydrochloride XR + PlaceboEisaiApproved
✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06515418Phase 2Terminated

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
35
MK0557MerckPhase 3
40
AMG 786AmgenPhase 1
29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
39
TirzepatideEli LillyPhase 2
42
exenatide + PlaceboEli LillyApproved
43
BrenipatideEli LillyPhase 1
36
Orforglipron + PlaceboEli LillyPhase 3
47
TERN-601Terns PharmaceuticalsPhase 2
32
MBX 4291 + PlaceboMBX BiosciencesPhase 1
30
PG-102Rani TherapeuticsPhase 1
26
Orforglipron + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
Eloralintide + PlaceboEli LillyPhase 1
29
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
29
TirzepatideEli LillyApproved
50
Adenosine + RegadenosonAstellas PharmaPre-clinical
26
Micafungin + MicafunginAstellas PharmaApproved
43
MicafunginAstellas PharmaApproved
43